Gerd Zettlmeissl

Gerd Zettlmeissl has more than 30 years of R&D and General Management leadership experience in the biopharmaceutical industry. Since 2012 he served on the Board of Directors of several non-profit organizations and biotech companies.
 Until 2015 he was chairman of GlycoVaxyn (Switzerland, now GSK), an and until 2020 chairman of Themis (Austria, now MSD). He is the former CEO of the Austria-based biotechnology company Intercell (now Valneva). While at Intercell  from 2001 to 2011, he built the company from a private start-up  to a publicly listed international organization with more than 400 employees. Prior to joining Intercell he was Managing Director of Chiron-Behring (Germany) and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron (USA) and Behringwerke (Germany). In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Gerd Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post-doctoral fellowship in virology at the Institut Pasteur. 

He currently chairs the Supervisory Boards of Medigene (Germany), MSD Wellcome Trust Hilleman Laboratories (Singapore) and MinervaX (Denmark) and serves as a member of the Scientific Advisory Boards  of Biological E (India), CureVac (Germany) and Wacker Biosolutions (Germany).